OptraSCAN immune-oncology solution for Programmed Death Ligand 1 expression on tumor and immune cells
The field of immune-oncology biomarker is exploding dramatically. Immunotherapy agents overcome tumor evasion through targeted immune checkpoint inhibitors and scientifically driven combination therapies including multiple immune-stimulating and chemotherapeutic agents. However, not all patients are benefited from immunotherapy and precision medicine requires tremendous understanding of the tumor microenvironment. Complex tissue architecture, heterogeneous biomarker expression as well as visual …